CDRH's Schultz sees no significance in trials warning trend
This article was originally published in Clinica
Executive Summary
An unusually high number of warning letters over a recent one-year period might suggest that medical device companies are finding it challenging to comply with the FDA's regulations for conducting clinical trials.